S17 Ep57: Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

S17 Ep57: Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

July 20, 2026 · 38 min · Season 17 · Episode 57

About this episode

Experts discuss evolving immunotherapy strategies for stage I to III non-small cell lung cancer.

Highlights from the PER® CME activity "Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Tina Cascone, MD, PhD; Puneeth Iyengar, MD, PhD; and Paula A. Ugalde Figueroa, MD; discuss evolving immunotherapy strategies for stage I to III non–small cell lung cancer (NSCLC), spanning surgical work-up and the shifting definition of resectability, perioperative immunotherapy trial data, the way that pathologic response guides treatment decisions, and the integration of radiation with immunotherapy in unresectable disease. Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/tumor-board-evolving-immunotherapy-strategies-for-stage-i-iii-nsclc-1 This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full…

Sponsors

AstraZeneca Pharmaceuticals

More episodes of OncLive® On Air

Explore listener stats, chart rankings, contacts and more on the OncLive® On Air podcast page.